|
1
|
Alexanian C, Liakos W, Toussi A, Kao J, Cheng MY, Wang EA, Nava J, Tran M, Marusina AI, Merleev AA, Leal AR, Fung MA, Le ST, Luxardi G, Maverakis E. Immune profiling of lupus miliaris disseminatus faciei and successful management with anti-tumour necrosis factor therapy. Clin Exp Dermatol 2021; 46:910-914. [PMID: 33864395 DOI: 10.1111/ced.14684] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 04/12/2021] [Indexed: 11/29/2022]
Abstract
Lupus miliaris disseminatus faciei (LMDF) is a chronic inflammatory dermatosis of unknown aetiology, most often seen in young adults. Although many treatments for LMDF exist, treatment guidelines have not been developed, and response to therapy is generally unpredictable. We present the results of transcriptomic analysis of LMDF lesional skin, which revealed a variety of differentially expressed genes linking LMDF to alterations in innate and adaptive T helper 1 immunity. Immunohistochemical analysis was also performed, identifying similar changes in T-cell immune responses. Given evidence for increased tumour necrosis factor (TNF) pathway activity, our patient, who had previously been refractory to multiple treatments, was initiated on TNF inhibitor therapy with excellent response. This characterization of the LMDF immune response may lead to improved treatment of this condition.
Collapse
Affiliation(s)
- C Alexanian
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - W Liakos
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - A Toussi
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - J Kao
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - M Y Cheng
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - E A Wang
- Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, USA
| | - J Nava
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - M Tran
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - A I Marusina
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - A A Merleev
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - A R Leal
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - M A Fung
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA.,Department of, Pathology, University of California, Davis, Sacramento, CA, USA
| | - S T Le
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - G Luxardi
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| | - E Maverakis
- Departments of, Department of, Dermatology, University of California, Davis, Sacramento, CA, USA
| |
Collapse
|
|
2
|
Kim BS, Maverakis E, Alexanian C, Wang JZ, Raychaudhuri SP. Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review. J Cutan Med Surg 2020; 24:278-284. [PMID: 32238066 PMCID: PMC7238506 DOI: 10.1177/1203475420914622] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.
Collapse
Affiliation(s)
- Byung-Soo Kim
- 34996 Department of Dermatology, Pusan National University College of Medicine, Busan, Korea.,Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| | - Emanual Maverakis
- 481070 Department of Dermatology, University of California School of Medicine, Davis, CA, USA
| | - Clarie Alexanian
- 481070 Department of Dermatology, University of California School of Medicine, Davis, CA, USA.,Georgetown University School of Medicine, Washington, DC, USA
| | - Jenny Z Wang
- 481070 Department of Dermatology, University of California School of Medicine, Davis, CA, USA
| | - Siba P Raychaudhuri
- 156053 VA Medical Center Sacramento, Division of Rheumatology & Immunology, Mather, CA, USA.,12218 Division of Rheumatology, Allergy & Clinical immunology, University of California School of Medicine, Davis, CA, USA
| |
Collapse
|